NUVB
Nuvation BioDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
9
U.S. public peers
Grade Position
Below peers
vs peer average
NUVB vs peer average
32/100
NUVB vs. peer average (D vs. C)
Grade spread
A 2 · B 2 · C 1 · D 3 · F 1
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
BMY is the first available peer comparator.
Bristol Myers Squibb's Augtyro competes in ROS1-positive lung cancer, but BMY's diversified scale makes its valuation multiple a poor direct benchmark for NUVB. [BMS announcement](https://news.bms.com/news/details/2023/US-Food-and-Drug-Administration-Approves-Augtyro/default.aspx).
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
NUVB
Nuvation Bio
BMY
Bristol-Myers Squibb
Grade
D
A
Momentum
13
64
Value
41
67
Sentiment
66
57
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Constructive
Grade position vs BMY
NUVB / BMY
Grade Position
Below peers
NUVB vs. peer average (D vs. C)
32/100
Momentum
13
BMYValue
41
BMYSentiment
66
NUVBRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs NUVB
BMY is the first peer returned for this comparison set.